Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Management of patients with chronic kidney disease.

Schena FP.

Intern Emerg Med. 2011 Oct;6 Suppl 1:77-83. doi: 10.1007/s11739-011-0688-2.

PMID:
22009616
2.

Implementing KDOQI CKD definition and staging guidelines in Southern California Kaiser Permanente.

Rutkowski M, Mann W, Derose S, Selevan D, Pascual N, Diesto J, Crooks P.

Am J Kidney Dis. 2009 Mar;53(3 Suppl 3):S86-99. doi: 10.1053/j.ajkd.2008.07.052.

PMID:
19231766
3.

Treatment of hypertension in chronic kidney disease.

Toto RD.

Semin Nephrol. 2005 Nov;25(6):435-9. Review.

PMID:
16298269
4.

The 2004 Canadian recommendations for the management of hypertension: Part II--Therapy.

Khan NA, McAlister FA, Campbell NR, Feldman RD, Rabkin S, Mahon J, Lewanczuk R, Zarnke KB, Hemmelgarn B, Lebel M, Levine M, Herbert C; Canadian Hypertension Education Program.

Can J Cardiol. 2004 Jan;20(1):41-54.

PMID:
14968142
5.

The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part II - Therapy.

Khan NA, McAlister FA, Rabkin SW, Padwal R, Feldman RD, Campbell NR, Leiter LA, Lewanczuk RZ, Schiffrin EL, Hill MD, Arnold M, Moe G, Campbell TS, Herbert C, Milot A, Stone JA, Burgess E, Hemmelgarn B, Jones C, Larochelle P, Ogilvie RI, Houlden R, Herman RJ, Hamet P, Fodor G, Carruthers G, Culleton B, Dechamplain J, Pylypchuk G, Logan AG, Gledhill N, Petrella R, Tobe S, Touyz RM; Canadian Hypertension Education Program.

Can J Cardiol. 2006 May 15;22(7):583-93.

6.

[Electrolyte and acid-base balance disorders in advanced chronic kidney disease].

Alcázar Arroyo R.

Nefrologia. 2008;28 Suppl 3:87-93. Spanish.

7.

[Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].

Cases Amenós A, Goicoechea Diezhandiño M, de Alvaro Moreno F.

Nefrologia. 2008;28 Suppl 3:39-48. Spanish.

8.

The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part II - therapy.

Khan NA, McAlister FA, Lewanczuk RZ, Touyz RM, Padwal R, Rabkin SW, Leiter LA, Lebel M, Herbert C, Schiffrin EL, Herman RJ, Hamet P, Fodor G, Carruthers G, Culleton B, DeChamplain J, Pylypchuk G, Logan AG, Gledhill N, Petrella R, Campbell NR, Arnold M, Moe G, Hill MD, Jones C, Larochelle P, Ogilvie RI, Tobe S, Houlden R, Burgess E, Feldman RD; Canadian Hypertension Education Program.

Can J Cardiol. 2005 Jun;21(8):657-72.

PMID:
16003449
9.

[When to start dialysis. The predialysis patient].

Triolo G, Savoldi S.

G Ital Nefrol. 2008 May-Jun;25 Suppl 41:S9-12, discussion S13-20. Italian.

PMID:
18473314
10.

Interim evidence of the renoprotective effect of the angiotensin II receptor antagonist losartan versus the calcium channel blocker amlodipine in patients with chronic kidney disease and hypertension: a report of the Japanese Losartan Therapy Intended for Global Renal Protection in Hypertensive Patients (JLIGHT) Study.

Iino Y, Hayashi M, Kawamura T, Shiigai T, Tomino Y, Yamada K, Kitajima T, Ideura T, Koyama A, Sugisaki T, Suzuki H, Umemura S, Kawaguchi Y, Uchida S, Kuwahara M, Yamazaki T; Japanese Lasartan Therapy Intended for the Global Renal Protection in Hypertensive Patients (JLIGHT) Study Investigators.

Clin Exp Nephrol. 2003 Sep;7(3):221-30.

PMID:
14586719
11.

Factors affecting survival in advanced chronic kidney disease patients who choose not to receive dialysis.

Wong CF, McCarthy M, Howse ML, Williams PS.

Ren Fail. 2007;29(6):653-9. Erratum in: Ren Fail. 2008;30(3):343.

PMID:
17763158
12.

Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers for diabetic nephropathy: a retrospective comparison.

Robles NR, Romero B, Fernandez-Carbonero E, Sánchez-Casado E, Cubero JJ.

J Renin Angiotensin Aldosterone Syst. 2009 Dec;10(4):195-200. doi: 10.1177/1470320309352352.

PMID:
20026868
13.

Achieving chronic kidney disease treatment targets in renal transplant recipients: results from a cross-sectional study in Spain.

Marcén R, del Castillo D, Capdevila L, Fernandez-Fresnedo G, Rodrigo E, Cantarell C, Fernández-Rodriguez A, López-Oliva MO, Camps J, Aljama P, Ortuño J, Arias M.

Transplantation. 2009 May 15;87(9):1340-6. doi: 10.1097/TP.0b013e3181a23837.

PMID:
19424034
14.

Effect of Lisinopril on the progression of renal insufficiency in mild proteinuric non-diabetic nephropathies.

Cinotti GA, Zucchelli PC; Collaborative Study Group.

Nephrol Dial Transplant. 2001 May;16(5):961-6.

PMID:
11328901
17.

Effect of blood pressure lowering on markers of kidney disease progression.

Udani SM, Koyner JL.

Curr Hypertens Rep. 2009 Oct;11(5):368-74. Review.

PMID:
19737454
18.
19.

Nonrandomized trial of weight loss with orlistat, nutrition education, diet, and exercise in obese patients with CKD: 2-year follow-up.

MacLaughlin HL, Cook SA, Kariyawasam D, Roseke M, van Niekerk M, Macdougall IC.

Am J Kidney Dis. 2010 Jan;55(1):69-76. doi: 10.1053/j.ajkd.2009.09.011. Epub 2009 Nov 17.

PMID:
19926371
20.

Variability and risk factors for kidney disease progression and death following attainment of stage 4 CKD in a referred cohort.

Levin A, Djurdjev O, Beaulieu M, Er L.

Am J Kidney Dis. 2008 Oct;52(4):661-71. doi: 10.1053/j.ajkd.2008.06.023.

PMID:
18805347

Supplemental Content

Support Center